Evidence map›Paper›PMID 39578473›Full record

ArticleNature communications2024

Lysosomal "TRAP": a neotype modality for clearance of viruses and variants.

Chengliang Lyu, Zhanlong He, Xiaoming Hu, Shuang Wang, Meng Qin, Li Zhu, Yanyan Li, Fengmei Yang, Zhouguang Jiao, Xiao Zhang and 13 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Chengliang Lyu *State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.ORCID http://orcid.org/0000-0002-3999-3199
Zhanlong He *Institute of Medical Biology, Peking Union Medical College & Chinese Academy of Medical Sciences, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, 650118, China.
Xiaoming Hu *State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Shuang WangState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.ORCID http://orcid.org/0000-0002-9189-602X
Meng QinBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.
Li ZhuState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing, 100071, China.ORCID http://orcid.org/0000-0001-9975-8978
Yanyan LiInstitute of Medical Biology, Peking Union Medical College & Chinese Academy of Medical Sciences, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, 650118, China.
Fengmei YangInstitute of Medical Biology, Peking Union Medical College & Chinese Academy of Medical Sciences, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, 650118, China.
Zhouguang JiaoState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Xiao ZhangState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
Guihong LuState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.ORCID http://orcid.org/0000-0002-9160-9588
Erqiang WangSinovac Life Sciences Co., Ltd., Beijing, 100085, China.
Yaling HuSinovac Life Sciences Co., Ltd., Beijing, 100085, China.
Yu ZhaiSinovac Life Sciences Co., Ltd., Beijing, 100085, China.
Youchun WangDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, 102629, China.ORCID http://orcid.org/0000-0001-9769-5141
Weijin HuangDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, 102629, China.ORCID http://orcid.org/0000-0002-4246-8889
Dongshu WangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing, 100071, China.
Yimin CuiDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Xiaocong PangDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Xiangzheng LiuDepartment of thoracic surgery, Peking University First Hospital, Beijing, 100034, China.
Hidehiro KamiyaGraduate School of Bio-Applications and Systems Engineering, Tokyo University of Agriculture and Technology, Tokyo, 184-8588, Japan.
Guanghui MaState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China. ghma@ipe.ac.cn.ORCID http://orcid.org/0000-0001-9154-5556
Wei WeiState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China. weiwei@ipe.ac.cn.ORCID http://orcid.org/0000-0002-6244-3187

Funding

National Natural Science Foundation of China (National Science Foundation of China) 21821005
6 · The paper itself

Abstract

The binding of viruses to host-entry factor receptors is an essential step for viral infection. Many studies have shown that macrophages can internalize viruses and degrade them in lysosomes for clearance in vivo. Inspired by these natural behaviors and using SARS-CoV-2 as a testbed, we harvest lysosomes from activated macrophages and anchor the protein-receptor ACE2 as bait, thus constructing a lysosomal "TRAP" (lysoTRAP) that selectively captures, internalizes, and eventually degrades SARS-CoV-2. Through experiments with cells, female mice, female hamsters, and human lung organoids, we demonstrate that lysoTRAP effectively clears SARS-CoV-2. Importantly, unlike therapeutic agents targeting SARS-CoV-2 spike protein, lysoTRAP remains effective against nine pseudotyped variants and the authentic Omicron variant, demonstrating its resistance to SARS-CoV-2 mutations. In addition to the protein-receptor ACE2, we also extend lysoTRAP with the saccharide-receptor sialic acid and verify its excellent antiviral effect against H1N1, highlighting the flexibility of our "TRAP" platform in fighting against various viruses.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19LysosomesSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsAntiviral AgentsCricetinaeFemaleHEK293 CellsHumansLungMacrophagesMiceOrganoidsVirus InternalizationACE2 protein, humanAngiotensin-Converting Enzyme 2Antiviral AgentsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID39578473
PMCPMC11584657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.